Artesunate-clindamycin multi-kinetics and site-specific oral delivery system for antimalaric combination products
- Publication Type:
- Journal Article
- Citation:
- Journal of Controlled Release, 2010, 146 (1), pp. 54 - 60
- Issue Date:
- 2010-08-01
Closed Access
| Filename | Description | Size | |||
|---|---|---|---|---|---|
 | 2011005964OK.pdf | 296.73 kB |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
The aim of this work was to study a multi-kinetics and site-specific oral antimalaria drug delivery system (MKS_DDS), containing artesunate and clindamycin, based on the Dome Matrix® module assembly technology. The MKS_DDS assembled system comprises of four modules, i.e., two controlled release (CR) modules for delivery of 160. mg of clindamycin phosphate, one immediate release module containing 50. mg of artesunate and one immediate release module containing 80. mg of clindamycin phosphate. These modules have been assembled in stacked and void configurations. The void configuration is able to float and showed gastro-retentive behavior. The MKS_DDS was investigated for its mechanical characteristics, system behavior during release, drug release rate and mechanism.A bioavailability study (dogs) showed that the clindamycin plasma curve of the MKS_DDS system exhibited a quasi constant release rate, up to 8. h.The MKS_DDS system containing clindamycin and artesunate allows the use of one tablet containing one immediate release dose of artesunate and of clindamycin and a portion of clindamycin released over a prolonged time, by exploiting the gastro-retentive properties of a floating system. © 2010 Elsevier B.V.
Please use this identifier to cite or link to this item: